Science & Technology
Fri, January 21, 2011Thu, January 20, 2011Wed, January 19, 2011Tue, January 18, 2011Mon, January 17, 2011Fri, January 14, 2011Thu, January 13, 2011Wed, January 12, 2011Tue, January 11, 2011Mon, January 10, 2011Fri, January 7, 2011Thu, January 6, 2011Wed, January 5, 2011Tue, January 4, 2011Mon, January 3, 2011Fri, December 31, 2010Thu, December 30, 2010Wed, December 29, 2010Tue, December 28, 2010Mon, December 27, 2010OPSENS DEVELOPS SECOND DIAGNOSTIC TOOL FOR FFR MEASUREMENT
Published in Science and Technology on Monday, January 10th 2011 at 9:31 GMT by Market Wire
QUEBEC CITY, Jan. 10 /CNW Telbec/ - Opsens Inc. ("Opsens") (TSX-V: OPS) announces that it has recently filed a patent application for the OptoWire, a second diagnostic tool to assess coronary lesions by doing Fractional Flow Reserve ("FFR").
Opsens' in-house team has been developing the OptoWire in parallel with the EasyWire, unveiled at the end of December 2010, also for use in FFR.
OptoWire for the measurement of FFR
Unlike traditional guide wires, the OptoWire is a guide wire instrumented with a fiber optic pressure sensor, which is drift free and provides a high fidelity measurement of blood pressure in coronary arteries. In addition to more reliable measurement, the OptoWire offers better mechanical performance in terms of trackability, torquability and support over other existing pressure guide wires.
"Opsens is developing a complete tool box for cardiologists to use in the measurement of FFR, allowing them to select the right tool for each individual patient," said Claude Belleville, VP Medical. "OptoWire and EasyWire are complementary products: a cardiologist may choose the OptoWire for a diffused lesion or easy-to-reach lesions, while the EasyWire may be better suited for lesions that are more difficult to reach."
FFR supported by strong clinical data
Fractional Flow Reserve is an index of the functional severity of a coronary stenosis that is calculated from pressure measurements taken before and after a narrowing of the arteries during coronary arteriography. This new approach enables an "on the spot" diagnosis for a better assessment as to whether a stent is an appropriate intervention to improve blood circulation in the cardiovascular system.
FFR measurement is an increasingly popular method used in the treatment of cardiac lesions. The FAME Study, published in 2009, outlined the positive outcome this step has on patients' recovery and overall outcome, reducing death rates by over 30%.
About Opsens Inc. ([ www.opsens.com ])
Opsens is a leading developer, manufacturer and supplier of a wide range of fiber optic sensors and associated signal conditioners based on proprietary patented and patent pending technologies. Opsens' sensors provide long-term accuracy and reliability in the harshest environments. Opsens provides sensors to measure pressure, temperature, strain and displacement to original equipment manufacturers (OEM) and end-users in the oil and gas, medical, and laboratory fields. Opsens provides complete technical support, including installation, training, after-sales service, for its fiber optics systems that are regulated by the ISO 9001-2008 norm.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.
